Pan Cancer T Expands Seed Funding Round With Additional Funding From Existing Shareholders And New Investor Thuja Capital | No more news

0

Pan Cancer T Expands Seed Funding Cycle With Additional Funding From Existing Shareholders And New Investor Thuja Capital

– The enlarged investor union strengthens the company’s financial position and its investor base

ROTTERDAM, The Netherlands I October 28, 2021 I Pan Cancer T BV, a biotechnology spin-off of Erasmus MC dedicated to the discovery and development of novel TCR-T therapies against solid tumors, today announced the completion of an extended seed investment round . All current shareholders participated in the round, with Thuja Capital as the new investor. The undisclosed proceeds are in addition to the initial seed capital funding announced earlier this year. The company’s syndicate of experienced life science venture capitalists now includes Van Herk Ventures, Swanbridge Capital and Thuja Capital as well as founding shareholder Erasmus MC.

Katrien Reynders-Frederix, CEO of Pan Cancer T, said: “Despite some successes in adoptive cell therapy such as chimeric antigen receptor (CAR) T cell therapy, the vast majority of solid cancers remain refractory to such treatments. TCR-T cell therapy is a promising new option that has demonstrated significant clinical benefits in patients with various solid tumors. With the extended seed cycle and continued support from our investors, we will be able to advance our core program and strengthen our preclinical assets. Then we will prepare to raise a Series A funding round to advance our main program in the clinic.

Michel Briejer, Investment Manager at Thuja Capital adds: “Since we identified Pan Cancer T as an investment opportunity, we have been deeply impressed by the quality of the science, the team and its advisors. We are delighted to join the shareholder base and serve on the Supervisory Board to help and support Pan Cancer T towards the success it is destined to achieve. “

Dharminder Chahal, Director of Investments at Van Herk and Swanbridge Capital, said: “I am happy to see that Pan Cancer T has made such progress in just one year after its founding. I am convinced that the company will continue this high rate of development thanks to this additional investment.

Professor Chris Bangma, Professor in the Department of Urology at Erasmus University Medical Center Rotterdam, said: “Erasmus MC values ​​the development of new therapeutic options for its patients. The results of immune therapy in various tumors are beyond expectations. Many patients can benefit from the new, carefully designed immunological approaches and clinical evaluation. Therefore, Erasmus MC is happy to support Pan Cancer T in this journey. ”

About Pan Cancer T

Pan Cancer T was founded in late 2020 and as a spin-off of Erasmus MC (Rotterdam, The Netherlands) to advance first-class TCR TCR cell therapies for hard-to-treat solid tumors. The Company’s approach includes three differentiating elements. First, it exploits unique targets for T cells that are exclusively expressed by multiple solid cancers. Second, it applies innovative technologies to select natural and highly specific TCRs that recognize these targets. Third, he is developing therapies that overcome tumor microenvironmental challenges in targeted cancers. The Company has ongoing R&D programs to develop safe and effective adoptive T cell therapies suitable for large cohorts of patients with triple negative breast cancer as well as bladder and ovarian cancers. , colorectum, prostate, skin, esophagus, lung or brain. For more information, please visit: www.pancancer-t.com

About Swanbridge Capital

Swanbridge Capital is a start-up venture capital fund that focuses on (pre) seed investments in the life sciences industry. The fund invests in the development of new therapies, diagnostics and medical devices. Swanbridge Capital was founded in 2016 and is headquartered in Rotterdam, the Netherlands. For more information: www.swanbridgecapital.nl

About Van Herk Ventures

Van Herk Ventures is part of the Rotterdam-based Van Herk Groep and has a portfolio of investments in real estate, energy and life sciences. The Van Herk Groep invests in the life sciences sector through direct investments in private and listed companies and in venture capital funds. Major investments include Galapagos, Zealand Pharma, BioInvent, DCprime, Ablynx (sold to Sanofi) and Crucell (sold to J&J). For more information: www.vanherkgroep.nl/beleggingen

About the Erasmus Medical Center

Erasmus MC is the largest university medical center in the Netherlands. The main objective of Erasmus ™ is the establishment and maintenance of a healthy population. Nearly 14,000 employees are dedicated to providing exceptional care, facilitating world-class education and conducting pioneering research. These professionals contribute to the development of expertise on health and disease. They connect the latest scientific knowledge with practical treatments and preventive measures, thus providing maximum benefit to patients and at the same time enabling people to live healthier lives. For more information: www.erasmusmc.nl

About Thuja Capital

Thuja Capital Management (Thuja) manages several venture capital funds aiming to create and develop companies in the fields of (bio) pharmaceutical, medical technologies and digital health. In addition to generating a financial return for its investors, Thuja’s investments have a positive impact on the health and well-being of patients. Thuja serves physicians and patients around the world by locally providing capital to daring entrepreneurs with revolutionary product concepts. For more information visit www.thuyacapital.com.

THE SOURCE: Pan Cancer T


Source link

Leave A Reply

Your email address will not be published.